Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Sridhar Viswanathan"'
Autor:
Shweta Singh, Laura Serwer, Amy DuPage, Kristi Elkins, Niharika Chauhan, Matthew Ravn, Fritz Buchanan, Leyu Wang, Michael Krimm, Ken Wong, Jason Sagert, Kimberly Tipton, Stephen J. Moore, Yuanhui Huang, Andrew Jang, Eric Ureno, Adam Miller, Sarah Patrick, Shanti Duvur, Shouchun Liu, Olga Vasiljeva, Yingchun Li, Tracy Henriques, Ilaria Badagnani, Shawn Jeffries, Siew Schleyer, Rob Leanna, Claus Krebber, Sridhar Viswanathan, Luc Desnoyers, Jonathan Terrett, Marcia Belvin, Susan Morgan-Lappe, W. Michael Kavanaugh, Jennifer Richardson
Publikováno v:
Molecular Cancer Therapeutics. 21:1326-1336
Probody therapeutics (Pb-Txs) are conditionally activated antibody–drug conjugates (ADCs) designed to remain inactive until proteolytically activated in the tumor microenvironment, enabling safer targeting of antigens expressed in both tumor and no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb073726d937f7e11b7d94e91eed5013
https://doi.org/10.1158/1535-7163.mct-21-0193
https://doi.org/10.1158/1535-7163.mct-21-0193
Autor:
Jennifer Richardson, W. Michael Kavanaugh, Susan Morgan-Lappe, Marcia Belvin, Jonathan Terrett, Luc Desnoyers, Sridhar Viswanathan, Claus Krebber, Rob Leanna, Siew Schleyer, Shawn Jeffries, Ilaria Badagnani, Tracy Henriques, Yingchun Li, Olga Vasiljeva, Shouchun Liu, Shanti Duvur, Sarah Patrick, Adam Miller, Eric Ureno, Andrew Jang, Yuanhui Huang, Stephen J. Moore, Kimberly Tipton, Jason Sagert, Ken Wong, Michael Krimm, Leyu Wang, Fritz Buchanan, Matthew Ravn, Niharika Chauhan, Kristi Elkins, Amy DuPage, Laura Serwer, Shweta Singh
Supplementary Data from Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody–Drug Conjugate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::734c4baf0734abf8c7e252b8e10c6fd0
https://doi.org/10.1158/1535-7163.22523304.v1
https://doi.org/10.1158/1535-7163.22523304.v1
Autor:
Fujiko Takamura, Erik E. Karrer, Yasuyuki Higashi, Steven J. Chapin, Margaret Neighbors, Sridhar Viswanathan, Hidekazu Mizuhara, Shinsuke Oshima, Yasutomo Fujii, Bruce H. Devens
Publikováno v:
International Immunopharmacology. 40:310-317
The CTLA4-Ig fusion proteins abatacept and belatacept inhibit CD28-mediated T cell activation by binding CD80 (B7-1) and CD86 (B7-2) costimulatory ligands and are clinically proven immunosuppressants used for rheumatoid arthritis and renal transplant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98ff00ad001bd419bd264871d2b736f8
https://doi.org/10.1016/j.intimp.2016.09.009
https://doi.org/10.1016/j.intimp.2016.09.009
Autor:
Kuoting Wu, Clifford Wong, Margaret Neighbors, Erik E. Karrer, Yasuyuki Higashi, Madan M. Paidhungat, Steven J. Chapin, Steven H. Bass, Bruce H. Devens, Shinsuke Oshima, Margaret Reed, Brent R. Larsen, Yonghong Chen, Francisco A. Anderson, Marc Whitlow, Rujuta A. Bam, Sridhar Viswanathan, Rong A. Fan, Qian Zhang
Publikováno v:
Protein Engineering Design and Selection. 29:159-167
The CTLA4-Ig therapeutics abatacept and belatacept inhibit CD28-mediated T cell activation by binding CD80 (B7-1) and CD86 (B7-2) co-stimulatory ligands. Both compounds preferentially bind CD80, yet CD86 has been implicated as the dominant co-stimula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e16578a205d00bb45328a4431b02b5c0
https://doi.org/10.1093/protein/gzw002
https://doi.org/10.1093/protein/gzw002
Publikováno v:
International Journal of Production Economics. 163:61-70
Despite the increasing importance of integrating suppliers into buyer product development activities, the majority of the research on supplier integration focuses on total cost reduction and benefits to the buyer rather than cost sharing between a bu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe93bd2f718930e6e89eb51eb2439556
https://doi.org/10.1016/j.ijpe.2015.02.004
https://doi.org/10.1016/j.ijpe.2015.02.004
Autor:
Yasutomo Fujii, Takahisa Noto, Yasuyuki Higashi, Steven J. Chapin, Margaret Neighbors, Yuka Kawato, Shinsuke Oshima, B. Devens, Masashi Maeda, Sridhar Viswanathan, Susumu Tsujimoto, Jun Hirose, Hidehiko Fukahori, Fujiko Takamura, Erik E. Karrer, Koji Nakamura, Takanori Marui
Publikováno v:
Transplantation. 100(12)
Background Blockade of CD28-mediated T cell costimulation by a modified cytotoxic T lymphocyte-associated antigen 4 (CTLA4-Ig), belatacept, is a clinically effective immunosuppressive therapy for the prevention of renal allograft rejection. Use of be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20fd00138a6907188d0b97a98d07cdb8
https://pubmed.ncbi.nlm.nih.gov/27861289
https://pubmed.ncbi.nlm.nih.gov/27861289
Publikováno v:
Journal of Operations Management. 29:318-328
This study examines how individual purchasing agents function as boundary spanners with suppliers to influence trust development in themselves and the buying firms that employ them. Building upon boundary theory and supply chain cooperation research,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52e252c6b75a24137d5ebc2184b24579
https://doi.org/10.1016/j.jom.2010.07.001
https://doi.org/10.1016/j.jom.2010.07.001
Autor:
Hong Lu, Shouchun Liu, Sridhar Viswanathan, Michael Kavanaugh, Claus M. Krebber, Shweta Singh, William Mylott, Robert Leanna, Badagnani Ilaria, Jennifer Richardson, Niharika Chauhan, Henriques Tracy, Susan Morgan-Lappe, Serwer Laura Patterson
Publikováno v:
Molecular Cancer Therapeutics. 17:B103-B103
CX-2029 is a protease-activatable antibody prodrug (ProbodyTM Therapeutic) targeted against CD71 (transferrin receptor) and conjugated to a vcMMAE cytotoxic payload with a purified Drug to Probody Ratio (DPR) of 2. In the intact, prodrug form, each l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f091d86c8caf363e45c46c199efefad1
https://doi.org/10.1158/1535-7163.targ-17-b103
https://doi.org/10.1158/1535-7163.targ-17-b103
Autor:
Yuanhui Huang, Shouchun Liu, Adam Miller, Serwer Laura Patterson, Jennifer Richardson, Matthew M. Ravn, Shweta Singh, Michael Krimm, Michael P. Kavanaugh, Niharika Chauhan, Badagnani Ilaria, Andrew Jang, Rob Leanna, Ken Wong, Sarah Patrick, Claus M. Krebber, Henriques Tracy, Fritz G. Buchanan, Sridhar Viswanathan, Shanti Duvur, Eric Ureno, Amy DuPage, Susan Morgan-Lappe
Publikováno v:
Molecular Cancer Therapeutics. 17:B116-B116
ProbodyTM therapeutics are antibody prodrugs designed to remain largely inactive until proteolytically activated in the tumor microenvironment (TME), potentially enabling the safer targeting of antigens that are highly expressed in both tumor and nor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a45c41479baf9927bb2e03c3e55d52c3
https://doi.org/10.1158/1535-7163.targ-17-b116
https://doi.org/10.1158/1535-7163.targ-17-b116
Publikováno v:
Protein Expression and Purification. 59:223-231
Specific proteolytic cleavage of the gp120 subunit of the HIV-1 envelope (Env) glycoprotein in the third variable domain (V3) has previously been reported to occur in several cell lines, including Chinese hamster ovary cells that have been used for p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7d6f4c10d87574daf47b130f9e5652e
https://doi.org/10.1016/j.pep.2008.02.002
https://doi.org/10.1016/j.pep.2008.02.002